

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jeremy Curnock Cook
Date of last notice	28 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	5 June 2024 (United States) / 6 June 2024 (Australia) - RSUs and Options 6 June 2024 (United States) / 7 June 2024 (Australia) – Common Stock

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>6,175 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CHES Depositary Interests ("CDIs") ("RSUs")</p> <p>14,439 common stock of the Company (which may be represented by CDIs) ("Common Stock")</p> <p>2,550 Options expiring 23 Dec 2031 ex USD \$12.18</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17</p>
Class	<p>a. RSUs</p> <p>b. Options expiring 6 June 2034, ex USD \$9.51</p> <p>c. Common Stock</p>
Number acquired	<p>a. 9,200 RSUs</p> <p>b. 3,943 Options expiring 6 June 2034, ex USD \$9.51</p> <p>c. 6,175 Common Stock</p>
Number disposed	6,175 RSUs
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil consideration
No. of securities held after change	<p>9,200 RSUs</p> <p>20,614 Common Stock</p> <p>2,550 Options expiring 23 Dec 2031 ex USD \$12.18</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17</p> <p>3,943 Options expiring 6 June 2034, ex USD \$9.51</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<p>Issue of Options and RSUs as approved by Shareholders at the 2024 AGM.</p> <p>Issue of Common Stock upon conversion of Restricted Stock Units (RSUs)</p>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.